Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
time starting salary is normally in the range £32,546 to £35,116 with potential progression once in post to £39,355 Grade: 7 Full Time, Fixed Term contract up to August 2028 Closing date: 25th August
-
potential progression once in post to £86,760 Grade: 9 Full Time, Permanent Closing date: 27th August 2025 Role Summary We are seeking a creative, thoughtful and collaborative colleague who will lead the
-
progression once in post to £62,728 Grade: 8 Full Time, Permanent Closing date: 13th July 2025 Our offer to you People are at the heart of what we are and do. The University of Birmingham is proud to have been
-
celebrate their success. We are committed to helping the people who work here to develop through our sector-leading Birmingham Professional programme which provides all professional services staff with
-
progression once in post to £62,728 Grade: 8 Part Time (15 hours per week) Fixed Term contract up to July 2027 Closing date: 10th August 2025 Academic Development Programme - new Assistant Professors will
-
to £55,755 with potential progression once in post to £62,728 Grade: 8 Part Time (18.75 hours per week) Permanent Closing date: 14th August 2025 Academic Development Programme - new Assistant Professors will
-
emergencies PCOS SEVa – a national programme addressing variation in the quality of care for polycystic ovary syndrome (PCOS) Role Summary Work within specified research grants and contribute to writing bids
-
to £45,413 with potential progression once in post to £48,149 As this vacancy has limited funding the maximum salary that can be offered is Grade 7, salary £37,174 Full Time, Fixed Term contract up to December
-
, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with potential progression once in post to £48,149 Grade: 7 Full Time, Fixed Term contract up to October 2030
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor